KR20240005110A - 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법 - Google Patents

비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20240005110A
KR20240005110A KR1020237043697A KR20237043697A KR20240005110A KR 20240005110 A KR20240005110 A KR 20240005110A KR 1020237043697 A KR1020237043697 A KR 1020237043697A KR 20237043697 A KR20237043697 A KR 20237043697A KR 20240005110 A KR20240005110 A KR 20240005110A
Authority
KR
South Korea
Prior art keywords
compound
subject
negative
activities
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020237043697A
Other languages
English (en)
Korean (ko)
Inventor
레미 루트링거
마이클 데이비슨
Original Assignee
미쓰비시 타나베 파마 코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미쓰비시 타나베 파마 코퍼레이션 filed Critical 미쓰비시 타나베 파마 코퍼레이션
Publication of KR20240005110A publication Critical patent/KR20240005110A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020237043697A 2016-05-25 2017-05-23 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법 Ceased KR20240005110A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662341590P 2016-05-25 2016-05-25
US62/341,590 2016-05-25
PCT/US2017/034030 WO2017205393A1 (en) 2016-05-25 2017-05-23 Compositions and methods for treating negative symptoms in non-schizophrenic patients
KR1020187036656A KR20190013846A (ko) 2016-05-25 2017-05-23 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187036656A Division KR20190013846A (ko) 2016-05-25 2017-05-23 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법

Publications (1)

Publication Number Publication Date
KR20240005110A true KR20240005110A (ko) 2024-01-11

Family

ID=58794265

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237043697A Ceased KR20240005110A (ko) 2016-05-25 2017-05-23 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법
KR1020187036656A Ceased KR20190013846A (ko) 2016-05-25 2017-05-23 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187036656A Ceased KR20190013846A (ko) 2016-05-25 2017-05-23 비-조현병성 환자에서 음성 증상을 치료하기 위한 조성물 및 방법

Country Status (9)

Country Link
US (2) US20190216793A1 (https=)
EP (1) EP3463356A1 (https=)
JP (3) JP2019516756A (https=)
KR (2) KR20240005110A (https=)
CN (3) CN113908156A (https=)
PH (1) PH12018502445A1 (https=)
SG (2) SG10202011470UA (https=)
TW (2) TWI820001B (https=)
WO (1) WO2017205393A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3227273T3 (pl) 2014-12-02 2022-05-30 Minerva Neurosciences, Inc. Kompozycje zawierające 2-((1-(2-(4-fluorofenylo)-2-oksoetylo)piperydyn-4-ylo)metylo)izoindolin-1-on do leczenia schizofrenii
IL319156A (en) 2017-06-21 2025-04-01 Minerva Neurosciences Inc Controlled-release oral dosage forms are resistant to gastric acid.
EP3840835A1 (en) * 2018-08-21 2021-06-30 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
TWI879755B (zh) * 2020-02-20 2025-04-11 日商田邊三菱製藥股份有限公司 魯哌啶酮用於治療負性症狀及疾病、增加神經可塑性及促進神經保護的用途
KR102360137B1 (ko) * 2020-03-25 2022-02-08 주식회사 케이티앤지 카트리지 및 이를 포함하는 에어로졸 생성 장치
US11957675B2 (en) * 2021-02-09 2024-04-16 Xenon Pharmaceuticals Inc. Methods and uses for treating anhedonia
WO2024138073A1 (en) * 2022-12-21 2024-06-27 Woebot Labs, Inc. Administering a digital therapeutic using a device interface to treat anxiety or depression

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166617B2 (en) * 2000-02-29 2007-01-23 Mitsubishi Pharma Corporation Cyclic amide derivatives
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
US20090088449A1 (en) * 2006-02-07 2009-04-02 Mitsubishi Tanabe Pharma Corporation 4-acylaminopyridine derivative mediated neurogenesis
KR20080089279A (ko) * 2007-03-30 2008-10-06 미쓰비시 타나베 파마 코퍼레이션 우울증의 예방 및/또는 치료제
US8937900B2 (en) * 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
RS64819B1 (sr) * 2010-07-20 2023-12-29 Minerva Neurosciences Inc Metode upotrebe derivata cikličnih amida za lečenje šizofrenije i njenih simptoma
TWI520949B (zh) * 2010-07-20 2016-02-11 錫蘭尼克藥物有限公司 使用環醯胺衍生物治療σ受體介導之病症的方法
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
EP3144308B1 (en) * 2014-05-16 2020-06-24 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
PL3227273T3 (pl) * 2014-12-02 2022-05-30 Minerva Neurosciences, Inc. Kompozycje zawierające 2-((1-(2-(4-fluorofenylo)-2-oksoetylo)piperydyn-4-ylo)metylo)izoindolin-1-on do leczenia schizofrenii

Also Published As

Publication number Publication date
TW202335672A (zh) 2023-09-16
US20230190726A1 (en) 2023-06-22
PH12018502445A1 (en) 2019-09-09
JP2025000921A (ja) 2025-01-07
CN109689055A (zh) 2019-04-26
CN113694065A (zh) 2021-11-26
CN113908156A (zh) 2022-01-11
EP3463356A1 (en) 2019-04-10
JP2019516756A (ja) 2019-06-20
TWI820001B (zh) 2023-11-01
SG10202011470UA (en) 2021-01-28
US20190216793A1 (en) 2019-07-18
SG11201810358YA (en) 2018-12-28
JP2022188185A (ja) 2022-12-20
KR20190013846A (ko) 2019-02-11
TWI851224B (zh) 2024-08-01
WO2017205393A1 (en) 2017-11-30
TW201808288A (zh) 2018-03-16

Similar Documents

Publication Publication Date Title
US11680044B2 (en) Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
TWI851224B (zh) 非思覺失調症病患之負性症狀治療用醫藥組成物
JP2025510913A (ja) 双極性障害の処置のための５－ＭｅＯ－ＤＭＴ
US20250000881A1 (en) Treatment of treatment resistant depression with psilocybin
CN101557812A (zh) 3-α-雄甾烷二醇，可选地结合PDE5抑制剂在治疗性功能障碍中的应用
AU2023427992A1 (en) Treatment of mental disorders
JP2022526101A (ja) 重水素化デキストロメトルファン及びキニジンを使用して統合失調症の陰性症状を治療する方法
JP6053678B2 (ja) 統合失調症を処置するための環状アミド誘導体の使用の方法
WO2023114097A1 (en) Psilocybin and an adjunctive serotonin reuptake inhibitor for use in the treatment of treatment-resistant depression
AU2024229800A1 (en) Methods of treating essential tremor
US20240408086A1 (en) Use of luvadaxistat for the treatment of cognitive impairment
WO2026068950A1 (en) Pharmaceutical compositions of 5-meo-dmt for use in the treatment of alcohol use disorders
CN118488843A (zh) 用赛洛西宾治疗难治性抑郁症
HK1190945A (en) Use of testosterone and a 5-ht1a agonist in the treatment of sexual dysfunction
HK1135038B (en) Use of testosterone and a 5-ht1a agonist in the treatment of sexual dysfunction

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R13-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)